eseba-vec (HB-200) / Hookipa Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Enrollment open, Combination therapy, Surgery:  TARGET-HPV: TheraT (clinicaltrials.gov) -  Aug 15, 2022   
    P1/2,  N=98, Recruiting, 
    These changes in the microbial communities and their interactions may play an important role in tobacco resistance to black shank disease. Not yet recruiting --> Recruiting
  • ||||||||||  Trial initiation date, Combination therapy, Surgery:  TARGET-HPV: TheraT (clinicaltrials.gov) -  Apr 28, 2022   
    P1/2,  N=98, Not yet recruiting, 
    In the Phase 2 part of the study a combination of HB-201 at 5 × 106 units IV Q3W with pembrolizumab is being tested in HPV16+ HNSCC patients. Initiation date: Jan 2022 --> Jul 2022
  • ||||||||||  HB-201 / Hookipa Pharma
    In vitro and in vivo characterization of non-oncolytic engineered arenavirus vectors for cancer immunotherapy (Section 37) -  Mar 9, 2022 - Abstract #AACR2022AACR_4137;    
    P1/2
    In a therapeutic setting of the TC-1 tumor model, both vectors were comparably effective, showing major infiltration of CD8+ T cells into the tumor microenvironment, tumor growth delay and a significantly prolonged survival already after a single administration. In this data set we have confirmed the strong immunogenicity of the engineered arenavirus platform leading to efficient tumor control in a relevant mouse model for HPV16+ cancers, which further supports the clinical development of our novel arenavirus platform.
  • ||||||||||  New P1/2 trial, Combination therapy, Surgery:  TARGET-HPV: TheraT (clinicaltrials.gov) -  Nov 4, 2021   
    P1/2,  N=98, Not yet recruiting, 
  • ||||||||||  HB-201 / Hookipa Pharma, HB-202 / Hookipa Pharma
    Review, Journal:  Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. (Pubmed Central) -  Nov 1, 2021   
    This response can be further enhanced by alternating injections of HB-202 and HB-201, which has resulted in frequencies of circulating HPV16 E7/E6-specific CD8 T cells of up to 40% of the total CD8 T cell compartment in peripheral blood in analyses to date. Treatment with intravenous administration also resulted in a disease control rate of 73% among 11 evaluable patients with head and neck cancer dosed every three weeks, including 2 patients with a partial response.